Paul-Ehrlich-Institut

Immutep's Efti Shows Promise in Lung and Head & Neck Cancers, Advances Autoimmune Program

7 months ago

• Immutep's eftilagimod alfa (efti) in combination with pembrolizumab (KEYTRUDA®) receives positive FDA feedback for a Phase III trial in first-line non-small cell lung cancer (NSCLC). • Phase IIb trial (TACTI-003) results show efti plus KEYTRUDA® demonstrates efficacy and favorable safety in first-line head and neck cancer, particularly in PD-L1 negative tumors. • Immutep doses first participant in Phase I trial of IMP761, a novel LAG-3 agonist antibody, targeting autoimmune diseases, marking a significant milestone. • The company's strong financial position, with A$172.3 million, extends its cash reach to the end of CY2026, supporting ongoing clinical programs.